Background
The role of plasma β-amyloid biomarkers has been increasingly reported in Alzheimer's disease (AD) diagnosis and prognosis of cognitive decline both in vascular and neurodegenerative amyloidopathies [1] [2] [3] [4] [5] [6] [7] [8] . From the onset of neurodegenerative disorders throughout the temporal freeze of the AD process, 9 10 , it seems clear that cerebrospinal fluid (CSF) and plasma amyloid markers are highly relevant regardless of the stage of the disease:
from memory complaints to loss of autonomy status and/or mortality 1 . In order to improve diagnostic criteria at an early stage, some studies have focused on determining Aβ markers profile in population-based studies in subjects free of cognitive impairment as well as the curve of plasma β-amyloid concentrations over a person's lifetime and prognostic usefulness of plasma β-amyloid biomarkers in aging populations.
This domain raises new questions about the role of amyloid biomarkers in terms of the gaining prognosis. Surprisingly, very little is known about the physiological "role" of amyloid in plasma. As described in a few studies, concentrations of amyloid peptides increase with age [11] [12] [13] . The ratio between the two forms Aβ 1-40 and Aβ 1-42 is inversely associated with blood pressure values and risk of hypertension in the elderly 14 and also with depression 15 . Vascular risk factors including cholesterol and HbA1c are associated with higher concentrations of Aβ 1-42 16 . A recent report has suggested that higher dietary intakes of ω3-Poly-Unsaturated
Fatty Acids were associated with lower plasma concentrations of Aβ in cognitively healthy elderly subjects 17 .
It has been hypothesized that high plasma amyloid level was associated with mortality.
To address this issue, we studied whether plasma Aβ concentrations were associated with mortality risk in a subsample of the French Three-City (3C) prospective cohort study of men and women aged 65 and over. Being in this cohort framework enabled us to test if this association was independent from other factors previously linked to plasma Aβ concentrations and to potential mediators.
Methods
The study design, population and methods used have been described in our accompanying paper. Details of the 3C (three French cities: Bordeaux, Montpellier and Dijon)
population-based prospective study were also previously published 3 18 . Analyses were based on 1254 participants randomly selected from the initial cohort and stratified by center, sex and age in the frame of a nested case-cohort study to investigate biological variables ( Figure 1 , flow chart). Baseline amyloid concentrations were available for 1244 of them. We also ended up excluding 73 subjects for whom data on confounding factors were missing as well as 24 prevalent dementia cases diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria.
The standardized interview included questions on sociodemographic and lifestyle characteristics including hypertension, diabetes, history of vascular pathologies (stroke, angina pectoris, myocardial infarction and cardio-vascular surgery), diet (fruit, vegetables, fish, olive oil consumption), physical activity and chronic respiratory disorders as well as an inventory of all drugs used. For each participants, MCI status at baseline was defined according to the revised algorithm (MCI-R) based on a cross-sectional evaluation as suggested by an international consensus group 19 . In a subsample of the cohort (Bordeaux and Dijon centers), physical frailty was defined according to the Fried frailty criteria 20 , as indicated by the presence of at least three of the following criteria: weight loss, weakness, exhaustion, slowness and low activity level 21 .
The plasma Aβ peptide assay was performed using the INNO-BIA kit (Innogenetics, C, fibrinogen and plasma Aβ 1-40 . Although they were not significant we also added the study center, alcohol consumption, smoking habits, hypertension, fish intake, fruits and vegetables intake and physical activity to the models as they were associated with mortality for the whole sample. ApoE was not related to mortality (p=0.39) and thus was not included in the models.
The model named BASIC was adjusted for age (timescale), gender and study center. The CLASSIC CONFOUNDERS model also included educational level, occupation, BMI, smoking status, alcohol, history of chronic disorders, hypertension, depression, IADL, fruits and vegetables, fish, olive oil intake and physical activity.
Secondly, we tested the possible mediation effect of cognitive status and physical frailty in these elderly subjects based on two indicators: cognitive status (defined by MCI status at baseline, model MCI) and physical frailty defined only on a subsample (FRAILTY Model).
Furthermore, we examined whether associations between plasma amyloid marker and mortality observed in the CLASSIC CONFOUNDERS model were mediated by biological determinants. First, we studied renal functions through eGFR (under or over 60mg/ml) (Model KIDNEY FUNCTIONS). The role of systemic inflammation measured by fibrinogen was assessed (Model FIBRINOGEN). Finally, Cystatin C factor, related to renal functions and CSF amyloid metabolism was considered as a potential mediating factor (Model CYSTATIN C).
Analyses were performed using SAS software (version 9.2, SAS Institute Inc., Cary, NC).
Results
Baseline Characteristics (Table 1) . During the 8675 person-years of observation in a total of 1147 subjects, 215 deaths (mean follow-up 5.7 years SD=2.6) were registered while 932 participants remained alive (mean follow-up 8.0 years SD=1.4). The subjects who died were predominantly men (p<0.0001), older (p<0.0001) and current or former smoker (p=0.01).
They more often had a history of chronic disorders (p<0.0001), hypertension (p=0.01) and IADL impairment (p<0.0001). They were less often fish consumers (p=0.05), olive oil consumers (p=0.01) and practiced less physical activity (p=0.01). .0001) and fibrinogen (r=0.05, p=0.07). Cystatin C is highly correlated to e-GFR (r=-0.59, p<0.0001). All correlations are presented in Table 2 .
Plasma Aβ concentrations associated with mortality. Are correlations between plasma Aβ concentrations and mortality explained by biological systemic abnormalities? (Table 4) The association between risk of mortality and plasma Aβ 
Discussion
To the best of our knowledge, this is the first report highlighting that plasma concentrations of Aβ 1-40 and Aβ 1-40 / 1-42 ratio are associated with an increased risk of mortality in the elderly. Our study also brings forward arguments to try and answer the central question raised by our analyses: How can we explain such a relationship?
One of the first explanations might be that elderly subjects presented intra-cerebral lesions of AD at a prodromal stage of the disease, since we know that AD-related pathophysiological changes can occur many years before the onset of clinical dementia syndrome. First, we excluded all prevalent dementia cases from the analysis sample (n =24) and our complementary analyses did not validate this point.
When the Alzheimer's process is taken into account by including in all models baseline MCI status, the relationships between plasma amyloid Aβ 1-40 and Aβ 1-40 / 1-42 ratio and risk of mortality were not modified. Additionally, the pathological link between plasma Aβ concentrations and mortality was not observed for the Aβ 1-42 isoform, which is specifically altered in the Alzheimer's process. In the complementary analysis we also excluded the 72 incident dementia cases (Alzheimer's disease and other dementia), confirming the absence of an association between Aβ 1-42 and mortality which was previously evidenced in the Northern
Manathan cohort in a three-year follow-up 1 .
Another explanation for this association between plasma β-amyloid level and mortality risk in elderly subjects might be frailty. Frailty has been associated with an increased risk of death or adverse clinical outcomes independently of cognitive impairment 21 26-29 . Even though the potential association between frailty and plasma β-amyloid has not yet been observed in our sample (data not shown), some elements pointed to this possibility. Recently, β-2-microglobulin has been described as a marker of frailty in older adult 30 . Interestingly, β-2-microglobulin is known to be a component of amyloid fibrils in peripheral amyloidosis 31 32 and Aβ 1-40 fragment is more involved as a potential marker in amyloidosis and peripheral or cerebral angiopathy disorders. In our population, the frailty confounding factor did not alter the relationship between mortality and plasma Aβ 1-40 levels. However, we are aware of the limits of this frailty concept and the frailty composite score used in this study. So, the hypothesis that frailty is in fact the missing link between plasma Aβ level and mortality risk remains unanswered.
A mediator metabolic process either by an increased production of β-amyloid peptide via pro-inflammatory mechanisms or by a defect of the amyloid peptides clearance secondary to kidney function alteration could be another hypothesis. The notion of pro-inflammatory process caused by potential atherosclerotic lesions seems to quite relevant on many levels: (1) atherosclerosis plaques commonly seen in the elderly 33 ; (2) the major mechanism of atherosclerosis seems to be a chronic inflammation of the vessels 34 ; (3) showing that plasma Aβ 1-40 concentrations are independently associated with the diffuse small-vessel disease subtype 35 . However, the relationship we observed is in fact independent from the inflammation process assessed through fibrinogen as biomarkers; this was also true considering CRP levels (data not shown).
Interestingly, we unveiled that the positive relationship between higher plasma Aβ levels and increased mortality risk could be at least partially explained by the Cystatin C marker. Cystatin C belongs to the super family of the Cystatin type 2 and acts as an inhibitor of the Cystein protease (ie Cathepsins). Cystatin C is known to modulate the inflammatory response 36 and can be considered as a systemic inflammatory marker. However, further adjustments on fibrinogen did not modify the model CYSTATIN results. Secondly, we could have imagined that since Cystatin C was exploring kidney functions 37 it might be implied in the renal clearance of amyloid-β peptide. However, this link seems to be independent from kidney function alterations, as validated by the e-GFR. There is also evidence of Cystatin C role in Aβ metabolism and development of clinical AD 38 . Cystatin has been shown to be Although our results concern a single measurement of plasma β-amyloid concentrations their relevance is reinforced by the large number of potential confounding factors documented at baseline including markers of renal function and inflammation. We controlled for many factors known to be associated with mortality or plasma Aβ concentrations, such as gender 44 , age 1 11 44-46 , educational level 47 , cardiovascular factors 4 44 , hypertension 14 , atherosclerosis risk factors 16 , physical activity and diet 48 , depression 15 , body mass index 49 , tobacco and alcohol consumption 50 , diabetes and limitations in at least one of the IADL or impaired kidney functions 44 51 . Furthermore there was no interaction between amyloid levels and gender.
To conclude, plasma Aβ 1-40 is associated with mortality in our elderly population.
Further investigations are needed to determine more precisely plasma Aβ 1-40 and Cystatin C pathophysiological roles. In our era of preventive care management, the possibility of monitoring changes in plasma biomarkers after specific health/preventive interventions opens new opportunities in this field. 49 including a cut-off of >16 or current treatment for depression; e Limitations in at least one of the instrumental activities of daily living (IADL); f Fruits or vegetables intake at least once a day; g Fish/seafood intake at least once a week; h Olive oil: "no use", "moderate use": using olive oil for cooking or dressing alone or "high" use: using both for cooking and dressing; i Physical activity defined as regular when doing sport, active leisure or household physical activity regularly. All analyses were performed on 1147 subjects except for fibrinogen performed on 1118 subjects. CYSTATIN= CLASSICAL CONFOUNDERS + Cystatin C.
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